389
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

ORCID Icon, , , , , ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 3232-3236 | Received 09 May 2022, Accepted 17 Aug 2022, Published online: 10 Sep 2022
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

BJB receives funding from the National Institute of Health K12 grant # 5K12CA001727-27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.